Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...

Therapy options available for castration-resistant prostate cancer (CRPC) include secondary or more intensive hormone medicines, chemotherapy, immunotherapy, and radiation-related agents.

Prostate cancer is one of the most common cancers in the world. While many prostate cancers grow slowly and remain localized, ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

In patients with biochemical recurrence after prostate cancer surgery, the optimal duration of hormone therapy after salvage radiation therapy has been debated.

In a significant advancement for prostate cancer research, a first-of-its kind study led by Emory researchers uncovered how ...

Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...

Chicago Cubs great Ryne Sanberg faced prostate cancer with grace and openness. His goal was to help others. From the ...

Drs Sandhya Srinivas and Tanya B. Dorff discuss metastatic hormone-sensitive prostate cancer, which patients are the best candidates for doublets vs triplets, and how we pick these patients.

Prostate cancer is the most prevalent cancer in Australia. This article discusses the limitations of PSA tests in determining prostate cancer and highlights new guidelines for better detection and ...